GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer’s disease may not be among them.
Otsuka preps for July decision on centanafadine for ADHD
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.


